Company / Accounts Receivable
CytomX Therapeutics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.0M
FY2025
5-year range
$790.0K / $36.0M
FY2021-FY2025
Trend
-35.1%
vs FY2024
Sector context
#102 of 113
Health Care
What the data says
Among 113 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 10% for accounts receivable. Accounts Receivable has declined for 3 consecutive years, from $36M in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +20.3%.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -61.8%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 113This company $2.0M Sector average $1.1B
▼
-99.8% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s accounts receivable has declined for 3 consecutive years.
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2025, accounts receivable decreased 35.1% year-over-year.
- Ranks #102 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0M | -35.1% |
| FY2024 | $3.1M | -9.6% |
| FY2023 | $3.4M | -90.5% |
| FY2022 | $36.0M | +4455.2% |
| FY2021 | $790.0K | -1.0% |
| FY2020 | $798.0K | +6038.5% |
| FY2019 | $13.0K | -86.6% |
| FY2018 | $97.0K | -99.0% |
| FY2017 | $10.1M | +369.6% |
| FY2016 | $2.2M | +190.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026